Previous 10 | Next 10 |
2024-03-07 20:10:08 ET Myomo, Inc. (MYO) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Kim Golodetz - Investor Relations, LHA Paul Gudonis - Chairman & Chief Executive Officer Dave Henry - Chief Financial Officer Confere...
2024-03-07 16:13:24 ET More on Myomo Myomo: Navigating Market Pressures And CMS Reclassification Myomo announces $6M registered direct offering of common stock ELAB, KIND and RLX among pre-market losers Seeking Alpha’s Quant Rating on Myomo His...
Q4 total revenue of $4.8 million, up 18% over the prior year Addition of Medicare Part B patients to backlog results in record 183 MyoPro orders and insurance authorizations received in Q4, up 87% over the prior year Record backlog of 230 patients as of December 31, 2023 Introdu...
2024-03-06 17:35:58 ET More on Myomo Myomo: Navigating Market Pressures And CMS Reclassification Myomo announces $6M registered direct offering of common stock ELAB, KIND and RLX among pre-market losers Seeking Alpha’s Quant Rating on Myomo His...
2024-03-06 17:35:33 ET Major earnings expected after the bell on Thursday include: Costco Wholesale Corporation ( COST ) Broadcom ( AVGO ) DocuSign ( DOCU ) Marvell Technology ( MRVL ) Petróleo Brasileiro ( PBR ) Read the full article o...
2024-03-01 12:45:04 ET DENVER, Colo., Mar 01, 2024 ( 247marketnews.com )- Myomo, Inc. (NYSE: MYO ) reported, this morning, that the Centers for Medicare & Medicaid Services (CMS) posted the final Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) f...
Fees for codes L8701 and L8702 are effective as of April 1, 2024 Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper...
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for th...
Myomo, Inc. (NYSE American: MYO) ( “Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has closed its previously announced...
2024-01-17 09:59:55 ET More on Myomo Myomo: Navigating Market Pressures And CMS Reclassification Myomo: Market Severely Undervaluing Opportunity Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report ELAB, KIND and RLX among pre-market losers ...
News, Short Squeeze, Breakout and More Instantly...
2024-05-20 10:00:07 ET Ben Haynor from Lake Street issued a price target of $7.00 for MYO on 2024-05-20 08:41:00. The adjusted price target was set to $7.00. At the time of the announcement, MYO was trading at $3.64. MYO currently trades -34.77% versus its 52 week high o...
Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today ...
Claims Remitted for Payment by All Four Billing Regions Orthotics and Prosthetics Providers Beginning to Receive Reimbursement at Published Rates Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that...